Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free IXI Stock Alerts

IXICO (IXI) Competitors

IXICO logo
GBX 8.30 -0.80 (-8.79%)
As of 07/13/2026 11:42 AM Eastern
Compare

IXI vs. FARN, ORPH, REDX, HEMO, and ETX

Should you buy IXICO stock or one of its competitors? MarketBeat compares IXICO with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IXICO include Faron Pharmaceuticals Oy (FARN), Open Orphan (ORPH), Redx Pharma (REDX), Hemogenyx Pharmaceuticals (HEMO), and e-therapeutics (ETX). These companies are all part of the "biotechnology" industry.

How does IXICO compare to Faron Pharmaceuticals Oy?

IXICO (LON:IXI) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Faron Pharmaceuticals Oy has a net margin of 0.00% compared to IXICO's net margin of -24.98%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat IXICO's return on equity.

Company Net Margins Return on Equity Return on Assets
IXICO-24.98% -16.18% -10.40%
Faron Pharmaceuticals Oy N/A 45.13%-70.00%

In the previous week, IXICO had 6 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 6 mentions for IXICO and 0 mentions for Faron Pharmaceuticals Oy. IXICO's average media sentiment score of 0.06 beat Faron Pharmaceuticals Oy's score of 0.00 indicating that IXICO is being referred to more favorably in the media.

Company Overall Sentiment
IXICO Neutral
Faron Pharmaceuticals Oy Neutral

IXICO has a beta of 0.129, meaning that its share price is 87% less volatile than the broader market. Comparatively, Faron Pharmaceuticals Oy has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

IXICO has higher revenue and earnings than Faron Pharmaceuticals Oy. IXICO is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IXICO£7.28M2.50-£3.58M-£1.95N/A
Faron Pharmaceuticals OyN/AN/A-£60.23M-£22.07N/A

13.0% of IXICO shares are held by institutional investors. Comparatively, 2.5% of Faron Pharmaceuticals Oy shares are held by institutional investors. 3.0% of IXICO shares are held by company insiders. Comparatively, 2.7% of Faron Pharmaceuticals Oy shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

IXICO beats Faron Pharmaceuticals Oy on 8 of the 12 factors compared between the two stocks.

How does IXICO compare to Open Orphan?

Open Orphan (LON:ORPH) and IXICO (LON:IXI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Open Orphan has a net margin of 0.00% compared to IXICO's net margin of -24.98%. Open Orphan's return on equity of 0.00% beat IXICO's return on equity.

Company Net Margins Return on Equity Return on Assets
Open OrphanN/A N/A N/A
IXICO -24.98%-16.18%-10.40%

In the previous week, IXICO had 6 more articles in the media than Open Orphan. MarketBeat recorded 6 mentions for IXICO and 0 mentions for Open Orphan. IXICO's average media sentiment score of 0.06 beat Open Orphan's score of 0.00 indicating that IXICO is being referred to more favorably in the news media.

Company Overall Sentiment
Open Orphan Neutral
IXICO Neutral

13.0% of IXICO shares are held by institutional investors. 3.0% of IXICO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Open Orphan has higher revenue and earnings than IXICO.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Open Orphan£34.71M0.00N/AN/AN/A
IXICO£7.28M2.50-£3.58M-£1.95N/A

Summary

IXICO beats Open Orphan on 5 of the 9 factors compared between the two stocks.

How does IXICO compare to Redx Pharma?

IXICO (LON:IXI) and Redx Pharma (LON:REDX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

IXICO has higher revenue and earnings than Redx Pharma. IXICO is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IXICO£7.28M2.50-£3.58M-£1.95N/A
Redx Pharma£4.20M0.00-£33.16M-£0.10N/A

13.0% of IXICO shares are owned by institutional investors. Comparatively, 72.7% of Redx Pharma shares are owned by institutional investors. 3.0% of IXICO shares are owned by insiders. Comparatively, 18.4% of Redx Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Redx Pharma has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Redx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
IXICO-24.98% -16.18% -10.40%
Redx Pharma N/A -180.80%-43.95%

IXICO has a beta of 0.129, indicating that its stock price is 87% less volatile than the broader market. Comparatively, Redx Pharma has a beta of -0.53, indicating that its stock price is 153% less volatile than the broader market.

In the previous week, IXICO had 6 more articles in the media than Redx Pharma. MarketBeat recorded 6 mentions for IXICO and 0 mentions for Redx Pharma. IXICO's average media sentiment score of 0.06 beat Redx Pharma's score of 0.00 indicating that IXICO is being referred to more favorably in the media.

Company Overall Sentiment
IXICO Neutral
Redx Pharma Neutral

Summary

IXICO beats Redx Pharma on 8 of the 12 factors compared between the two stocks.

How does IXICO compare to Hemogenyx Pharmaceuticals?

Hemogenyx Pharmaceuticals (LON:HEMO) and IXICO (LON:IXI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

Hemogenyx Pharmaceuticals has higher earnings, but lower revenue than IXICO. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
IXICO£7.28M2.50-£3.58M-£1.95N/A

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
IXICO -24.98%-16.18%-10.40%

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. Comparatively, 13.0% of IXICO shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Comparatively, 3.0% of IXICO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, IXICO had 6 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 6 mentions for IXICO and 0 mentions for Hemogenyx Pharmaceuticals. IXICO's average media sentiment score of 0.06 beat Hemogenyx Pharmaceuticals' score of 0.00 indicating that IXICO is being referred to more favorably in the news media.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
IXICO Neutral

Hemogenyx Pharmaceuticals has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, IXICO has a beta of 0.129, indicating that its share price is 87% less volatile than the broader market.

Summary

IXICO beats Hemogenyx Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does IXICO compare to e-therapeutics?

e-therapeutics (LON:ETX) and IXICO (LON:IXI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

IXICO has higher revenue and earnings than e-therapeutics. IXICO is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
e-therapeutics£295K0.00-£10.06M-£0.02N/A
IXICO£7.28M2.50-£3.58M-£1.95N/A

e-therapeutics has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat e-therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
e-therapeuticsN/A -38.75% -29.10%
IXICO -24.98%-16.18%-10.40%

26.5% of e-therapeutics shares are held by institutional investors. Comparatively, 13.0% of IXICO shares are held by institutional investors. 59.4% of e-therapeutics shares are held by insiders. Comparatively, 3.0% of IXICO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, IXICO had 6 more articles in the media than e-therapeutics. MarketBeat recorded 6 mentions for IXICO and 0 mentions for e-therapeutics. IXICO's average media sentiment score of 0.06 beat e-therapeutics' score of 0.00 indicating that IXICO is being referred to more favorably in the news media.

Company Overall Sentiment
e-therapeutics Neutral
IXICO Neutral

e-therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market. Comparatively, IXICO has a beta of 0.129, indicating that its share price is 87% less volatile than the broader market.

Summary

IXICO beats e-therapeutics on 7 of the 12 factors compared between the two stocks.

Get IXICO News Delivered to You Automatically

Sign up to receive the latest news and ratings for IXI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IXI vs. The Competition

Export
MetricIXICOBiotechnology IndustryMedical SectorLON Exchange
Market Cap£18.18M£517.04M£7.05B£2.85B
Dividend Yield1.27%3.90%2.68%6.17%
P/E Ratio-4.263.4727.15368.18
Price / Sales2.506,436.17587.9284,612.72
Price / Cash2.2513.1329.2227.87
Price / Book0.4285.9310.757.49
Net Income-£3.58M-£96.07M£3.58B£5.89B
7 Day Performance-10.03%-0.93%-2.07%-0.19%
1 Month Performance-0.42%2.45%3.31%-1.00%
1 Year Performance-17.00%60.19%26.35%61.67%

IXICO Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IXI
IXICO
N/AGBX 8.30
-8.8%		N/A-16.2%£18.18M£7.28MN/A89
FARN
Faron Pharmaceuticals Oy
N/AGBX 40
-2.4%		N/A-81.2%£79.81MN/AN/A34
ORPH
Open Orphan
N/AN/AN/AN/A£67.09M£34.71MN/A179
REDX
Redx Pharma
N/AN/AN/AN/A£58.35M£4.20MN/A101
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 790
-0.9%		N/A+433.7%£53.72MN/AN/A14

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:IXI) was last updated on 7/14/2026 by MarketBeat.com Staff.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
They told you not to miss this one
The largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...
Thor Metals | Sponsoredtc pixel
When I found Rolls-Royce under $2, most people thought I was crazy
In 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...
Monument Traders Alliance | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Print this and keep it by your screen
Ever been right about a stock's direction and still lost money on the trade? It's almost never bad luck - it's...
Profits Run | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel